Effect of TA-CIN (HPV 16 L2E6E7) booster immunisation in vulval intraepithelial neoplasia patients previously vaccinated with TA-HPV (vaccinia virus encoding HPV 16/18 E6E7)

Davidson, EJ; Faulkner, RL; Sehr, P; Pawlita, M; Smyth, LJC; Burt, DJ; Tomlinson, AE; Hickling, J; Kitchener, HC; Stern, PL

Abstract

Heterologous prime-boost vaccination schedules employing TA-HPV, a vaccinia virus encoding HPV 16/18 E6 and E7, in combination with TA-CIN, an HPV 16 L2E6E7 fusion protein, may offer advantages over the use of either agent alone for the immunotherapy of human papillomavirus (HPV) type 16-associated vulval intraepithelial neoplasia (VIN). In the present study, 10 women with HPV 16-positive high grade VIN, previously primed with TA-HPV, received three booster immunisations with TA-CIN. All but one demonstrated HPV 16-specific proliferative T-cell and/or serological responses following vaccination. Three patients additionally showed lesion shrinkage or symptom relief, but no direct correlation between clinical and immunological responses was seen.

• Journal Article Type: Article
• Publication Date: Jan 1, 2004
• Deposit Date: Dec 23, 2010
• Journal: Vaccine
• Print ISSN: 0264-410X
• Publisher: Elsevier
• Peer Reviewed: Peer Reviewed
• Volume: 22
• Issue: 21-22
• Pages: 2722-2729
• DOI: https://doi.org/10.1016/j.vaccine.2004.01.049
• Publisher URL: http://dx.doi.org/10.1016/j.vaccine.2004.01.049